The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab

Paul N. Meyer, Kai Fu, Timothy Charles Greiner, Lynette M Smith, Jan Delabie, Randy Gascoyne, German Ott, Andreas Rosenwald, Rita Braziel, Elias Campo, Julie Marie Vose, Georg Lenz, Louis Staudt, Wing Chan, Dennis D. Weisenburger

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapies. Patients with any SPARC+ cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC positivity in the microenvironment also had a significantly longer event-free survival. Survival differences were mainly due to the prognostic effect of SPARC+ cells in activated B-cell (ABC)-type DLBCL, with no effect found in the germinal center B-cell-type DLBCL. Of clinical features examined, only the number of extranodal sites was significantly associated with SPARC expression. Multivariate analysis revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin. SPARC expression in the microenvironment of DLBCL can be used for prognostic purposes, determining a subgroup of patients with ABC DLBCL who have significantly longer survival. More aggressive chemotherapy protocols should be considered for patients with ABC DLBCL without SPARC+ stromal cells. CD68 expression by cells in the microenvironment did not predict survival.

Original languageEnglish (US)
Pages (from-to)54-61
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume135
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stromal Cells
Cysteine
Survival
Proteins
B-Lymphocytes
Cellular Microenvironment
Germinal Center
Tumor Microenvironment
Rituximab
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Multivariate Analysis
Drug Therapy

Keywords

  • CD68
  • Diffuse large B-cell lymphoma
  • Microenvironment
  • Prognosis
  • SPARC
  • Stromal cells
  • Tumor markers, biological

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. / Meyer, Paul N.; Fu, Kai; Greiner, Timothy Charles; Smith, Lynette M; Delabie, Jan; Gascoyne, Randy; Ott, German; Rosenwald, Andreas; Braziel, Rita; Campo, Elias; Vose, Julie Marie; Lenz, Georg; Staudt, Louis; Chan, Wing; Weisenburger, Dennis D.

In: American Journal of Clinical Pathology, Vol. 135, No. 1, 01.01.2011, p. 54-61.

Research output: Contribution to journalArticle

Meyer, PN, Fu, K, Greiner, TC, Smith, LM, Delabie, J, Gascoyne, R, Ott, G, Rosenwald, A, Braziel, R, Campo, E, Vose, JM, Lenz, G, Staudt, L, Chan, W & Weisenburger, DD 2011, 'The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab', American Journal of Clinical Pathology, vol. 135, no. 1, pp. 54-61. https://doi.org/10.1309/AJCPJX4BJV9NLQHY
Meyer, Paul N. ; Fu, Kai ; Greiner, Timothy Charles ; Smith, Lynette M ; Delabie, Jan ; Gascoyne, Randy ; Ott, German ; Rosenwald, Andreas ; Braziel, Rita ; Campo, Elias ; Vose, Julie Marie ; Lenz, Georg ; Staudt, Louis ; Chan, Wing ; Weisenburger, Dennis D. / The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. In: American Journal of Clinical Pathology. 2011 ; Vol. 135, No. 1. pp. 54-61.
@article{5b7211fe086442119d54a0fe6abf2f8a,
title = "The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab",
abstract = "The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapies. Patients with any SPARC+ cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC positivity in the microenvironment also had a significantly longer event-free survival. Survival differences were mainly due to the prognostic effect of SPARC+ cells in activated B-cell (ABC)-type DLBCL, with no effect found in the germinal center B-cell-type DLBCL. Of clinical features examined, only the number of extranodal sites was significantly associated with SPARC expression. Multivariate analysis revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin. SPARC expression in the microenvironment of DLBCL can be used for prognostic purposes, determining a subgroup of patients with ABC DLBCL who have significantly longer survival. More aggressive chemotherapy protocols should be considered for patients with ABC DLBCL without SPARC+ stromal cells. CD68 expression by cells in the microenvironment did not predict survival.",
keywords = "CD68, Diffuse large B-cell lymphoma, Microenvironment, Prognosis, SPARC, Stromal cells, Tumor markers, biological",
author = "Meyer, {Paul N.} and Kai Fu and Greiner, {Timothy Charles} and Smith, {Lynette M} and Jan Delabie and Randy Gascoyne and German Ott and Andreas Rosenwald and Rita Braziel and Elias Campo and Vose, {Julie Marie} and Georg Lenz and Louis Staudt and Wing Chan and Weisenburger, {Dennis D.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1309/AJCPJX4BJV9NLQHY",
language = "English (US)",
volume = "135",
pages = "54--61",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab

AU - Meyer, Paul N.

AU - Fu, Kai

AU - Greiner, Timothy Charles

AU - Smith, Lynette M

AU - Delabie, Jan

AU - Gascoyne, Randy

AU - Ott, German

AU - Rosenwald, Andreas

AU - Braziel, Rita

AU - Campo, Elias

AU - Vose, Julie Marie

AU - Lenz, Georg

AU - Staudt, Louis

AU - Chan, Wing

AU - Weisenburger, Dennis D.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapies. Patients with any SPARC+ cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC positivity in the microenvironment also had a significantly longer event-free survival. Survival differences were mainly due to the prognostic effect of SPARC+ cells in activated B-cell (ABC)-type DLBCL, with no effect found in the germinal center B-cell-type DLBCL. Of clinical features examined, only the number of extranodal sites was significantly associated with SPARC expression. Multivariate analysis revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin. SPARC expression in the microenvironment of DLBCL can be used for prognostic purposes, determining a subgroup of patients with ABC DLBCL who have significantly longer survival. More aggressive chemotherapy protocols should be considered for patients with ABC DLBCL without SPARC+ stromal cells. CD68 expression by cells in the microenvironment did not predict survival.

AB - The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapies. Patients with any SPARC+ cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC positivity in the microenvironment also had a significantly longer event-free survival. Survival differences were mainly due to the prognostic effect of SPARC+ cells in activated B-cell (ABC)-type DLBCL, with no effect found in the germinal center B-cell-type DLBCL. Of clinical features examined, only the number of extranodal sites was significantly associated with SPARC expression. Multivariate analysis revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin. SPARC expression in the microenvironment of DLBCL can be used for prognostic purposes, determining a subgroup of patients with ABC DLBCL who have significantly longer survival. More aggressive chemotherapy protocols should be considered for patients with ABC DLBCL without SPARC+ stromal cells. CD68 expression by cells in the microenvironment did not predict survival.

KW - CD68

KW - Diffuse large B-cell lymphoma

KW - Microenvironment

KW - Prognosis

KW - SPARC

KW - Stromal cells

KW - Tumor markers, biological

UR - http://www.scopus.com/inward/record.url?scp=79251502962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251502962&partnerID=8YFLogxK

U2 - 10.1309/AJCPJX4BJV9NLQHY

DO - 10.1309/AJCPJX4BJV9NLQHY

M3 - Article

VL - 135

SP - 54

EP - 61

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -